Toll-like receptor 9 agonists as cancer therapeutics

被引：53
|
作者：
Holtick, Udo [1 ,2 ]
Scheulen, Max E. [3 ]
von Bergwelt-Baildon, Michael S. [1 ,2 ]
Weihrauch, Martin R. [1 ,2 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] Univ Cologne, Lab Transplantat & Tumor Immunol, Max Eder Grp, D-50924 Cologne, Germany
[3] Univ Essen Gesamthsch, W German Canc Ctr, Dept Med Canc Res, Essen, Germany
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期
关键词：
cancer; immunotherapy; TLR9; agonists; vaccine; BACTERIAL CPG-DNA; PHASE-II TRIAL; NF-KAPPA-B; T-CELLS; IMMUNOSTIMULATORY ACTIVITY; DENDRITIC CELLS; MOLECULAR-PATTERNS; ANTITUMOR-ACTIVITY; INNATE IMMUNITY; GROWTH-FACTOR;
D O I：
10.1517/13543784.2011.553187
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials. Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.
引用
收藏
页码：361 / 372
页数：12
相关论文
共 50 条
  • [11] Clinical development of Toll-like receptor-9 agonists
    Schetter, Christian
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (01): : 75 - 75
  • [12] Toll-like receptors involved in the response to microbial pathogens: Development of agonists for toll-like receptor 9
    Schetter, C
    Vollmer, J
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (02) : 204 - 210
  • [13] The future of toll-like receptor therapeutics
    Parkinson, Tanya
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (01) : 21 - 31
  • [14] Toll-like receptor 9 in breast cancer
    Sandholm, Jouko
    Selander, Katri S.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [15] Radiotherapy and Toll-Like Receptor Agonists
    Marabelle, Aurelien
    Filatenkov, Alex
    Sagiv-Barfi, Idit
    Kohrt, Holbrook
    SEMINARS IN RADIATION ONCOLOGY, 2015, 25 (01) : 34 - 39
  • [16] Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
    Zhang, Christine
    Ben, Atheena
    Reville, Jade
    Calabrese, Victoria
    Villa, Nina Nicole
    Bandyopadhyay, Mausumi
    Dasgupta, Subhajit
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (09) : 1134 - 1140
  • [17] Toll-like receptor agonists targeted to cancer cell metabolism
    Mancini, Rock
    Nielsen, Amy
    Hantho, Joseph
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [18] Trial Watch: Toll-like receptor agonists in cancer immunotherapy
    Smith, Melody
    Garcia-Martinez, Elena
    Pitter, Michael R.
    Fucikova, Jitka
    Spisek, Radek
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2018, 7 (12):
  • [19] Trial Watch Toll-like receptor agonists for cancer therapy
    Vacchelli, Erika
    Eggermont, Alexander
    Sautes-Fridman, Catherine
    Galon, Jerome
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2013, 2 (08):
  • [20] Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs
    Yu, Dong
    Putta, Mallikarjuna R.
    Bhagat, Lakshmi
    Li, Yukui
    Zhu, FuGang
    Wang, Daqing
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    Agrawal, Sudhir
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (25) : 6411 - 6418
12345